Wellnex Life Limited (WNX) Fair Value & Analysis
Consumer Defensive · AU · Market cap A$4.0M
Fair value as of: Jun 26, 2026
Analysis
Wellnex Life Limited (WNX) currently trades at A$0.0430, while our model-based Fair Value estimate is A$0.0480 — implying the stock looks roughly 11.6% undervalued today. We read business quality at 92/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia, New Zealand, and the United Kingdom. The company offers topical anti-inflammatory creams, sprays, and roll-ons under the Pain Away brand; caffeine energy liquid capsules and multivitamins under the Wakey Wakey brand; sleep aid products under the Nighty Night brand; teeth whitening solutions under the Mr. Bright brand; pain relief capsules under the Wagner Liquigesics brand; medicinal cannabis under the Wellness Life brand; and over-the-counter medicines under the Pharmacy Own brand. It is also involved in the holding of intellectual properties and trademarks of its products; brand and pharma solution businesses; and investment activities. The company was formerly known as Wattle Health Australia Limited and changed its name to Wellnex Life Limited in June 2021. Wellnex Life Limited was incorporated in 2011 and is headquartered in Port Melbourne, Australia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Wellnex Life Limited (WNX) undervalued?
What is the fair value of WNX?
What is the quality score of WNX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.